Valion Bio agrees to sell 1,500 Series B preferred shares to 3i for $1.5 million in private placement

• Valion Bio entered a $1.5 million private placement with 3i, LP, issuing 1,500 Series B Non-Voting Convertible Preferred shares.
• Shares priced at USD 1,000 each; Series B Warrants to buy common stock also issued, with size and exercise price set by a prior agreement.
• Closing expected on or about Aug. 17, 2026; sale relied on Securities Act Section 4(a)(2) or Rule 506(b) exemptions.
• 3i and other investors to receive cash royalties totaling 5% of Velocity Bioworks gross revenue from third parties for 10 years.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valion Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-006501), on August 17, 2026, and is solely responsible for the information contained therein.